Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

29 Feb 2024
www.biospace.com
Financial Statement
Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights Recorded revenue of $400,000 in the fourth quarter of 2023 as the Company continued its previously communicated controlled commercial launch of its Platinum® instrument Finalizing commercial readiness for expected full commercial launch by the end of Q1 2024 Launched version 2 of its sequencing kit in early February 2024 and has begun shipping to customers Announced the Company’s third international distribution partner, TOMY Digital Biology Co. Ltd., based in Japan Announced the planned release of a version 3 of its sequencing kit by the end of Q3 2024 Provides full year 2024 financial guidance “We made great progress in the fourth quarter of 2023 and are seeing the early results of that work now, including the launch of our version 2 sequencing kit in early February 2024, significant progress on scaling up our commercial resources, and the addition of our third distributor to our international network”, said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “We are pleased with our ability to launch the version 2 sequencing kit well within the previously provided timeline. We are excited about the acceleration we are seeing in our R&D pipeline and believe we are in a strong position to deliver a steady cadence of product enhancements and new capabilities to the market in 2024 and beyond. A version 3 of our sequencing kit is under development now and we expect to deliver it to the market by the end of Q3 2024. We are also making solid progress across library prep and instrument development programs that we believe will fuel the future growth of the Company for years to come.” Hawkins continued, “With all the progress that we have made over the last year, coupled with finalizing our commercialization readiness, I am pleased to announce that we expect to commence our full commercial launch of our Platinum® instrument by the end of Q1 2024. We have also released full year 2024 financial guidance.” Fourth Quarter 2023 and Full Year 2023 Financial Results During the fourth quarter of 2023, the Company continued its controlled commercial launch of its Platinum instrument, recording revenue of $400,000. Gross profit was $178,000 and gross margin was 45%. For the full year ended December 31, 2023, the Company recorded revenue of $1.1 million, gross profit of $488,000, and gross margin of 45%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits. Total operating expenses were $28.1 million in the fourth quarter of 2023, compared to $38.8 million for the same period in the prior year, and $111.7 million for the full year ended December 31, 2023, compared to $123.8 million for the same period in the prior year. Adjusted total operating expenses were $26.3 million in the fourth quarter of 2023, compared to $25.3 million for the same period in the prior year, and adjusted total operating expenses for the full year ended December 31, 2023, were $98.9 million compared to $103.2 million for the same period in the prior year. Overall adjusted operating expenses for 2023 compared to 2022 have decreased as the Company focused on deploying capital in an efficient manner to R&D projects while still building commercial capabilities. Net loss was $22.0 million in the fourth quarter of 2023, compared to a net loss of $33.1 million in the same period of the prior year, and a net loss of $96.0 million for the full year ended December 31, 2023, compared to a net loss of $132.4 million for the same period in the prior year. Adjusted EBITDA was negative $25.1 million in the fourth quarter of 2023, compared to negative $24.5 million in the same period of the prior year, and negative $94.3 million for the full year ended December 31, 2023, compared to negative $100.6 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures, adjusted total operating expenses and adjusted EBITDA, is provided in a table included in this press release. As of December 31, 2023, the Company’s cash and cash equivalents and investments in marketable securities were $257.7 million. 2024 Financial Guidance For the full year 2024, the Company provided the following financial guidance: Revenue $3.7 - $4.2 million Adjusted total operating expenses Less than $103 million Total cash usage Less than $100 million The Company also maintains the expectation that the balance in cash and cash equivalents and investments in marketable securities of $257.7 million as of December 31, 2023 will provide a runway into 2026. Webcast and Conference Call Information Quantum-Si will host a conference call to discuss its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, at 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event. About Quantum-Si Incorporated Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X. Use of Non-GAAP Financial Measures This press release presents the non-GAAP financial measures “adjusted total operating expenses” and “adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2024. Forward Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. QUANTUM-SI INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts) (Unaudited) Three months ended December 31, Years ended December 31, 2023 2022 2023 2022 Revenue Product $ 377 $ - $ 1,031 $ - Service 23 - 51 - Total revenue 400 - 1,082 - Cost of revenue 222 - 594 - Gross profit 178 - 488 - Operating expenses: Research and development 16,437 18,157 67,025 72,062 Selling, general and administrative 11,624 11,203 44,634 42,296 Goodwill impairment - 9,483 - 9,483 Total operating expenses 28,061 38,843 111,659 123,841 Loss from operations (27,883) (38,843) (111,171) (123,841) Dividend income 2,262 2,013 9,536 5,301 Gain (loss) on marketable securities, net 3,774 2,180 5,587 (20,603) Change in fair value of warrant liabilities (197) 1,122 (278) 6,243 Other (expense) income, net (4) 388 366 458 Loss before provision for income taxes (22,048) (33,140) (95,960) (132,442) Provision for income taxes - - - - Net loss and comprehensive loss $ (22,048) $ (33,140) $ (95,960) $ (132,442) Net loss per common share attributable to common stockholders, basic and diluted $ (0.16) $ (0.24) $ (0.68) $ (0.95) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 141,575 139,849 141,300 139,255 QUANTUM-SI INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) (Unaudited) December 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 133,860 $ 84,319 Marketable securities 123,876 266,990 Accounts receivable, net of allowance of $0 and $0, respectively 368 - Inventory, net 3,945 - Prepaid expenses and other current assets 4,261 6,873 Total current assets 266,310 358,182 Property and equipment, net 16,275 16,849 Internally developed software 532 - Operating lease right-of-use assets 14,438 15,757 Other assets 695 697 Total assets $ 298,250 $ 391,485 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,766 $ 3,903 Accrued expenses and other current liabilities 8,277 10,434 Current portion of operating lease liabilities 1,566 1,369 Total current liabilities 11,609 15,706 Warrant liabilities 1,274 996 Operating lease liabilities 13,737 16,077 Other long-term liabilities 11 - Total liabilities 26,631 32,779 Stockholders' equity Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 121,832,417 and 120,006,757 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. 12 12 Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 19,937,500 shares issued and outstanding as of December 31, 2023 and December 31, 2022. 2 2 Additional paid-in capital 767,239 758,366 Accumulated deficit (495,634 ) (399,674 ) Total stockholders' equity 271,619 358,706 Total liabilities and stockholders' equity $ 298,250 $ 391,485 QUANTUM-SI INCORPORATED RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (in thousands) (Unaudited) Three months ended December 31, Years ended December 31, 2023 2022 2023 2022 Net loss $ (22,048 ) $ (33,140 ) $ (95,960 ) $ (132,442 ) Adjustments to reconcile to EBITDA: Dividend income (2,262 ) (2,013 ) (9,536 ) (5,301 ) Depreciation and amortization 1,093 795 4,156 2,584 EBITDA (23,217 ) (34,358 ) (101,340 ) (135,159 ) Adjustments to reconcile to Adjusted EBITDA: Goodwill impairment - 9,483 - 9,483 (Gain) loss on marketable securities, net (3,774 ) (2,180 ) (5,587 ) 20,603 Change in fair value of warrant liabilities 197 (1,122 ) 278 (6,243 ) Other expense (income), net 4 (388 ) (366 ) (458 ) Stock-based compensation 1,339 4,107 8,253 11,206 Restructuring costs 373 - 4,504 - Adjusted EBITDA $ (25,078 ) $ (24,458 ) $ (94,258 ) $ (100,568 ) Three months ended December 31, Years ended December 31, 2023 2022 2023 2022 Total operating expenses $ 28,061 $ 38,843 $ 111,659 $ 123,841 Adjustments to reconcile to Adjusted total operating expenses: Stock-based compensation (1,339 ) (4,107 ) (8,253 ) (11,206 ) Restructuring costs (373 ) - (4,504 ) - Goodwill impairment - (9,483 ) - (9,483 ) Adjusted total operating expenses $ 26,349 $ 25,253 $ 98,902 $ 103,152
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.